» Articles » PMID: 25539757

Lack of Efficacy of Psychological and Pharmacological Treatments of Disorders of Eating Behavior: Neurobiological Background

Overview
Journal BMC Psychiatry
Publisher Biomed Central
Specialty Psychiatry
Date 2014 Dec 26
PMID 25539757
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Treatments of eating disorders result too often in partial psychological and physical remission, chronicization, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this problem, we conducted three studies to identify the biochemical background of cognitive-behavioural psychotherapy (CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT + olanzapine in anorexics (AN) and bulimics (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion, plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet [3H]-Paroxetin-binding Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and physical alterations.

Methods: Study 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and [3H]-Par-binding in 14 AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Study 2 investigated the effects of 4 months of IBPP on plasma HVA in 15 AN and 17 BN outpatients. Study 3 investigated the effect of 3 months of CBT + olanzapine (5 mg/day) in 30 AN outpatients. The data were analyzed using one-way ANOVA for repeated measures for the changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated measures for the differences in the psychobiological data in the 3 groups, Spearman's test for the correlations between basal and final changes in the psychological and biological scores.

Results: Study 1 revealed significant amelioration of the psychopathology in the AN and BN patients, no effects on HVA, MHPG or Paroxetin binding Kd, and a significant increase in Par-binding Bmax only in the BN patients. Study 2 revealed a significant effect of IBPP on psychopathology in the AN and BN patients, and a significant increase in HVA only in the BN patients. Study 3 revealed a significant positive effect of CBT + olanzapine therapy on the psychopathology and increased HVA values. No correlations were observed in the 3 groups between biological and psychological effects of the three treatments.

Conclusions: Our data advance suggestions on the mechanism of action of the three therapies; however, the lack of correlations between biochemical and psychological effects casts doubt on their significance. Clinical Trials.gov. Identifier NCT01990755 .

Citing Articles

Predicting and comparing the long-term impact of lifestyle interventions on individuals with eating disorders in active population: a machine learning evaluation.

Irandoust K, Parsakia K, Estifa A, Zoormand G, Knechtle B, Rosemann T Front Nutr. 2024; 11:1390751.

PMID: 39171102 PMC: 11337873. DOI: 10.3389/fnut.2024.1390751.


Pharmacological Studies in Eating Disorders: A Historical Review.

Lewis Y, Bergner L, Steinberg H, Bentley J, Himmerich H Nutrients. 2024; 16(5).

PMID: 38474723 PMC: 11154472. DOI: 10.3390/nu16050594.


Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews.

Blanchet C, Guillaume S, Bat-Pitault F, Carles M, Clarke J, Dodin V J Clin Med. 2019; 8(2).

PMID: 30823566 PMC: 6406645. DOI: 10.3390/jcm8020278.


Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.

Bello N, Yeomans B Expert Opin Drug Saf. 2017; 17(1):17-23.

PMID: 29053927 PMC: 6095708. DOI: 10.1080/14740338.2018.1395854.


Altered baseline brain activity differentiates regional mechanisms subserving biological and psychological alterations in obese men.

Zhang B, Tian D, Yu C, Li M, Zang Y, Liu Y Sci Rep. 2015; 5:11563.

PMID: 26099208 PMC: 4477369. DOI: 10.1038/srep11563.

References
1.
Cassano G, Miniati M, Pini S, Rotondo A, Banti S, Borri C . Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Disord. 2003; 33(2):172-7. DOI: 10.1002/eat.10130. View

2.
Halmi K, Dekirmenjian H, Davis J, Casper R, Goldberg S . Catecholamine metabolism in anorexia nervosa. Arch Gen Psychiatry. 1978; 35(4):458-60. DOI: 10.1001/archpsyc.1978.01770280068007. View

3.
Kaye W . Neurobiology of anorexia and bulimia nervosa. Physiol Behav. 2008; 94(1):121-35. PMC: 2601682. DOI: 10.1016/j.physbeh.2007.11.037. View

4.
Rausch J, Johnson M, Li J, Hutcheson J, Carr B, Corley K . Serotonin transport kinetics correlated between human platelets and brain synaptosomes. Psychopharmacology (Berl). 2005; 180(3):391-8. DOI: 10.1007/s00213-005-2178-6. View

5.
Marazziti D, Perugi G, Deltito J, Lenzi A, Maremmani I, Placidi G . High-affinity 3H-imipramine binding sites: a possible state-dependent marker for major depression. Psychiatry Res. 1988; 23(2):229-37. DOI: 10.1016/0165-1781(88)90013-3. View